ERBB2 and breast cancer: This study aimed to evaluate the effectiveness of a triple-targeting regimen-Denosumab (D), Pertuzumab (P) and Trastuzumab (T)-for HER2-positive (HER2<sup>+</sup>) BC, and to assess the added value of immune checkpoint inhibitors (ICIs).